Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: J Thorac Oncol. 2015 May;10(5):e29–e31. doi: 10.1097/JTO.0000000000000478

Figure 2.

Figure 2

MET alteration and predicted outcomes. Each panel shows MET exon 14 and flanking DNA sequence with splicing events indicated by black lines followed by the resulting protein sequence. A) Normal MET sequence and splicing. The c-Cbl binding site (Y1021) is marked with a box. B) Effect of chr7:g.116412043G>C alteration (red, arrow) if splicing is unimpaired resulting in a p.D1028H substitution without deletion of exon 14. C) Alternately, as predicted by splice site algorithms, the variant could result in altered splicing with deletion of exon 14, as has been described for other MET splice site variants in lung cancer.